NCT02417129 - BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Lymphoma, Non-Hodgkin

Interventions

DRUG

Rituximab

BI 695500 375 mg/M2

DRUG

BI 695500

BI 695500 375 mg/M2

Trial Locations (21)

Boehringer Ingelheim Investigational Site, Muscle Shoals

Boehringer Ingelheim Investigational Site, Bakersfield

Boehringer Ingelheim Investigational Site, Burbank

Boehringer Ingelheim Investigational Site, Loma Linda

Boehringer Ingelheim Investigational Site, Albany

Boehringer Ingelheim Investigational Site, Northbrook

Boehringer Ingelheim Investigational Site, Pittsfield

Boehringer Ingelheim Investigational Site, Morristown

Boehringer Ingelheim Investigational Site, East Setauket

Boehringer Ingelheim Investigational Site, Fayetteville

Boehringer Ingelheim Investigational Site, Middletown

Boehringer Ingelheim Investigational Site, Corpus Christi

Boehringer Ingelheim Investigational Site, Ogden

Boehringer Ingelheim Investigational Site, Graz

Boehringer Ingelheim Investigational Site, Leuven

Boehringer Ingelheim Investigational Site, Namur

Boehringer Ingelheim Investigational Site, Plovdiv

Boehringer Ingelheim Investigational Site, Sofia

Boehringer Ingelheim Investigational Site, Zagreb

Boehringer Ingelheim Investigational Site, Brno

Boehringer Ingelheim Investigational Site, Prague